CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss including noncontrolling interests	$ (2,668)	$ (5,170)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities-
Amortization of identifiable intangible assets	2,080	1,658
Depreciation expense	3,057	3,161
Bad debt expense	741	839
Deferred tax expense (benefit)	(1,521)	(2,110)
Amortization of debt financing costs	57	56
Gain on sale of assets	(216)	(85)
Changes in the fair value of contingent earn-out obligations	30	95
Stock-based compensation expense	577	1,238
(Increase) decrease in-
Receivables, net	(905)	(1,720)
Inventories	(68)	(197)
Prepaid expenses and other current assets	(855)	1,231
Costs and estimated earnings in excess of billings	(6,409)	949
Other noncurrent assets	(2,077)	(790)
Increase (decrease) in-
Accounts payable and accrued liabilities	(10,349)	(17,392)
Billings in excess of costs and estimated earnings	(1,621)	(956)
Other long-term liabilities	331	127
Net cash used in operating activities	(19,816)	(19,066)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(2,094)	(2,360)
Proceeds from sales of property and equipment	420	247
Proceeds from businesses sold	39	39
Sale of marketable securities		2,000
Cash paid for acquisitions, earn-outs and intangible assets, net of cash acquired	(15)	(1,800)
Net cash used in investing activities	(1,650)	(1,874)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net borrowings on revolving line of credit	0
Payments on other long-term debt	(100)
Payments of dividends to shareholders	(1,853)	(1,880)
Share repurchase program	0
Shares received in lieu of tax withholding	0
Excess tax benefit of stock-based compensation	19	(13)
Proceeds from exercise of options	36	123
Net cash used in financing activities	(1,898)	(1,770)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(23,364)	(22,710)
CASH AND CASH EQUIVALENTS, beginning of period	51,237	86,346
CASH AND CASH EQUIVALENTS, end of period	$ 27,873	$ 63,636